Haisco Pharmaceutical Group (002653.SZ)

Executive Summary

Haisco Pharmaceutical Group is a publicly traded Chinese biopharmaceutical company focused on innovative drugs and generics across oncology, cardiovascular, respiratory, and other therapeutic areas. The company has a robust pipeline with several assets in mid-to-late-stage development. Notably, HSK39297, a potential treatment for IgA nephropathy, is in Phase 3 with patient recruitment underway, while HSK47388 for plaque psoriasis is in Phase 2. Haisco also has a diverse portfolio of earlier-stage candidates in anesthesia, pain, and pruritus. The company's commercial product base includes approved generics and its proprietary crisugabalin, which is being evaluated for new indications. Haisco's strong R&D capabilities and expanding pipeline position it for growth, though most key assets are still years from potential approval. The company's valuation of ~$64.6 billion reflects market optimism around its innovative pipeline.

Upcoming Catalysts (preview)

• H2 2027HSK39297 Phase 3 Enrollment Completion in IgA Nephropathy75% success
• Q4 2026HSK47388 Phase 2 Top-Line Data for Plaque Psoriasis60% success
• Q3 2026HSK3486 Phase 2 Trial Initiation in Anesthesia/Sedation80% success